VYNE Therapeutics (VYNE) Stock Forecast, Price Target & Predictions
VYNE Stock Forecast
VYNE Therapeutics stock forecast is as follows: an average price target of $5.75 (represents a 112.96% upside from VYNE’s last price of $2.70) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VYNE Price Target
The average price target for VYNE Therapeutics (VYNE) is $5.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.75 to $5.75. This represents a potential 112.96% upside from VYNE's last price of $2.70.
VYNE Analyst Ratings
According to 2 Wall Street analysts, VYNE Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYNE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
VYNE Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 14, 2024 | Joseph Pantginis | H.C. Wainwright | $5.75 | $2.11 | 172.51% | 112.96% |
The latest VYNE Therapeutics stock forecast, released on Jun 14, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $5.75, which represents a 172.51% increase from the stock price at the time of the forecast ($2.11), and a 112.96% increase from VYNE last price ($2.70).
VYNE Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.75 |
| Last Closing Price | $2.70 | $2.70 | $2.70 |
| Upside/Downside | -100.00% | -100.00% | 112.96% |
In the current month, the average price target of VYNE Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VYNE Therapeutics's last price of $2.70. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
VYNE Therapeutics's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave VYNE a "Buy" rating, the same as its previous rate.
VYNE Therapeutics Financial Forecast
VYNE Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $76.00K | $114.00K | $135.00K | $99.00K | $6.00K | $167.00K | $126.00K | $178.00K | $2.29M | $4.09M | $4.26M | $4.12M | $4.29M | $3.27M | $11.69M | $1.75M | - | $497.00K |
| Avg Forecast | $180.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $6.29M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $12.40M | $11.36M |
| High Forecast | $180.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $7.55M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $14.88M | $13.64M |
| Low Forecast | $180.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $5.03M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $9.92M | $9.09M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 14 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 10 | 16 | 8 | 11 | 17 | 14 |
| Surprise % | - | - | - | - | 0.51% | 0.76% | 2.70% | 0.02% | 0.10% | 3.34% | 1.26% | 0.49% | 0.57% | 0.86% | 0.67% | 0.86% | 0.91% | 0.99% | 7.37% | 1.12% | - | 0.04% |
VYNE Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $100.00K, with a low forecast of $100.00K, and a high forecast of $100.00K. VYNE's average Quarter revenue forecast represents a 31.58% increase compared to the company's last Quarter revenue of $76.00K (Dec 23).
VYNE Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 14 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 10 | 16 | 8 | 11 | 17 | 14 |
| EBITDA | - | - | - | - | $-5.45M | $-6.23M | $-10.32M | $-5.88M | $-7.75M | $-9.08M | $-8.22M | $-8.65M | $-11.99M | $-17.78M | $-18.82M | $-19.46M | $-22.27M | $-23.42M | $-166.52M | $-39.07M | $-18.68M | $-12.65M |
| Avg Forecast | $-180.00K | $-110.00K | $-110.00K | $-37.60M | $-150.00K | $-150.00K | $-50.00K | $-29.72M | $-17.10M | $-50.00K | $-100.00K | $-23.50M | $-4.02M | $-4.76M | $-6.35M | $-21.36M | $-4.71M | $-3.31M | $-1.59M | $-34.42M | $-19.48M | $-11.50M |
| High Forecast | $-180.00K | $-110.00K | $-110.00K | $-30.08M | $-150.00K | $-150.00K | $-50.00K | $-23.78M | $-13.68M | $-50.00K | $-100.00K | $-18.80M | $-4.02M | $-4.76M | $-6.35M | $-17.09M | $-4.71M | $-3.31M | $-1.59M | $-27.54M | $-15.58M | $-9.20M |
| Low Forecast | $-180.00K | $-110.00K | $-110.00K | $-45.12M | $-150.00K | $-150.00K | $-50.00K | $-35.67M | $-20.53M | $-50.00K | $-100.00K | $-28.19M | $-4.02M | $-4.76M | $-6.35M | $-25.63M | $-4.71M | $-3.31M | $-1.59M | $-41.31M | $-23.37M | $-13.80M |
| Surprise % | - | - | - | - | 36.30% | 41.56% | 206.36% | 0.20% | 0.45% | 181.68% | 82.23% | 0.37% | 2.98% | 3.73% | 2.96% | 0.91% | 4.73% | 7.07% | 104.99% | 1.13% | 0.96% | 1.10% |
undefined analysts predict VYNE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VYNE Therapeutics's previous annual EBITDA (undefined) of $NaN.
VYNE Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 14 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 10 | 16 | 8 | 11 | 17 | 14 |
| Net Income | - | - | - | - | $-6.19M | $-6.58M | $-10.06M | $-5.62M | $-7.76M | $-9.46M | $-8.48M | $4.67M | $-11.57M | $-21.29M | $-19.92M | $-20.55M | $-23.18M | $-24.71M | $-167.44M | $-40.23M | $-18.87M | $-12.66M |
| Avg Forecast | $-13.20M | $-10.01M | $-8.09M | $-39.70M | $-21.29M | $-32.37M | $-109.87M | $-31.39M | $-16.33M | $-120.09M | $-132.23M | $-24.81M | $-190.10M | $-235.07M | $-267.20M | $-22.55M | $-406.27M | $-503.73M | $-741.00M | $-35.45M | $-18.87M | $-11.51M |
| High Forecast | $-11.68M | $-10.01M | $-8.09M | $-31.76M | $-21.29M | $-32.37M | $-109.87M | $-25.11M | $-13.06M | $-120.09M | $-132.23M | $-19.85M | $-190.10M | $-235.07M | $-267.20M | $-18.04M | $-406.27M | $-503.73M | $-741.00M | $-28.36M | $-15.10M | $-9.21M |
| Low Forecast | $-14.22M | $-10.01M | $-8.09M | $-47.64M | $-21.29M | $-32.37M | $-109.87M | $-37.66M | $-19.60M | $-120.09M | $-132.23M | $-29.77M | $-190.10M | $-235.07M | $-267.20M | $-27.07M | $-406.27M | $-503.73M | $-741.00M | $-42.54M | $-22.65M | $-13.81M |
| Surprise % | - | - | - | - | 0.29% | 0.20% | 0.09% | 0.18% | 0.48% | 0.08% | 0.06% | -0.19% | 0.06% | 0.09% | 0.07% | 0.91% | 0.06% | 0.05% | 0.23% | 1.13% | 1.00% | 1.10% |
VYNE Therapeutics's average Quarter net income forecast for Jun 22 is $-132.23M, with a range of $-132.23M to $-132.23M. VYNE's average Quarter net income forecast represents a -2931.47% decrease compared to the company's last Quarter net income of $4.67M (Mar 22).
VYNE Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 14 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 10 | 16 | 8 | 11 | 17 | 14 |
| SG&A | - | - | - | - | $3.88M | $3.03M | $3.22M | $3.24M | $3.71M | $3.95M | $4.30M | $4.42M | $8.20M | $13.83M | $15.84M | $16.62M | $17.90M | $19.77M | $26.46M | $25.41M | $3.75M | $2.70M |
| Avg Forecast | $4.49M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $156.77M | $1.50M | $1.25M | $2.49M | $9.14M | $100.18M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $3.75M | $2.45M |
| High Forecast | $4.49M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $188.13M | $1.50M | $1.25M | $2.49M | $9.14M | $100.18M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $4.50M | $2.94M |
| Low Forecast | $4.49M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $125.42M | $1.50M | $1.25M | $2.49M | $9.14M | $100.18M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $3.00M | $1.96M |
| Surprise % | - | - | - | - | 1.04% | 0.81% | 2.58% | 0.02% | 2.48% | 3.17% | 1.73% | 0.48% | 0.08% | 0.12% | 0.10% | 0.14% | 0.15% | 0.24% | 0.67% | 0.65% | 1.00% | 1.10% |
VYNE Therapeutics's average Quarter SG&A projection for Mar 24 is $2.49M, based on 1 Wall Street analysts, with a range of $2.49M to $2.49M. The forecast indicates a -35.85% fall compared to VYNE last annual SG&A of $3.88M (Dec 23).
VYNE Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 14 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 10 | 16 | 8 | 11 | 17 | 14 |
| EPS | - | - | - | - | $-0.60 | $-2.01 | $-3.07 | $-1.73 | $-2.60 | $-2.94 | $-2.63 | $1.44 | $-3.89 | $-7.36 | $-6.98 | $-7.57 | $-8.54 | $-10.61 | $-86.95 | $-68.14 | $-58.35 | $-51.83 |
| Avg Forecast | $-0.31 | $-0.23 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-58.18 | $-0.60 |
| High Forecast | $-0.27 | $-0.23 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-58.18 | $-0.48 |
| Low Forecast | $-0.33 | $-0.23 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-58.18 | $-0.72 |
| Surprise % | - | - | - | - | 1.20% | 2.64% | 1.19% | 0.07% | 0.80% | 1.04% | 0.85% | -0.50% | 0.87% | 1.33% | 1.11% | 0.96% | 0.90% | 0.90% | 5.00% | 1.79% | 1.00% | 86.38% |
According to 8 Wall Street analysts, VYNE Therapeutics's projected average Quarter EPS for Jun 22 is $-3.10, with a low estimate of $-3.10 and a high estimate of $-3.10. This represents a -315.63% decrease compared to VYNE previous annual EPS of $1.44 (Mar 22).
VYNE Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $2.08 | $12.00K | 576823.08% | - |
| FWBI | Entero Therapeutics | $2.96 | $270.00 | 9021.62% | Buy |
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| LGVN | Longeveron | $1.98 | $10.00 | 405.05% | Buy |
| GOVX | GeoVax Labs | $2.43 | $8.00 | 229.22% | Buy |
| ZURA | Zura Bio | $3.16 | $10.00 | 216.46% | Buy |
| LYRA | Lyra Therapeutics | $0.17 | $0.50 | 194.12% | Hold |
| VYNE | VYNE Therapeutics | $2.70 | $5.75 | 112.96% | Buy |
| KRON | Kronos Bio | $0.85 | $1.63 | 91.76% | Buy |
| SABS | SAB Biotherapeutics | $3.10 | $5.67 | 82.90% | Buy |
| CDTX | Cidara Therapeutics | $14.37 | $24.00 | 67.01% | Buy |
| AXLA | Axcella Health | $4.58 | $6.00 | 31.00% | Buy |
| VCYT | Veracyte | $35.94 | $35.00 | -2.62% | Buy |